Dr Reddy’s Laboratories has received establishment inspection report (EIR) from the US health regulator for a unit of its Srikakulam plant in Andhra Pradesh.

The company has received EIR from the United States Food and Drug Administration (USFDA) for its formulations manufacturing facility at Srikakulam unit II, Dr Reddy’s said in a filing to BSE.

The audit of the facility has been completed today with zero observations, the drug firm said.

The Custom Pharmaceutical Services (CPS) facility of Dr Reddys Laboratories Ltd at its Technology Development Centre (TDC-1), Miyapur has cleared the USFDA audit.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.